{"id":"lamotrigine-tablet","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Rash (including Stevens-Johnson syndrome risk)"},{"rate":"10-15","effect":"Dizziness"},{"rate":"5-10","effect":"Ataxia"},{"rate":"5-10","effect":"Diplopia"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Somnolence"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lamotrigine stabilizes neuronal membranes by blocking sodium channels, which prevents repetitive neuronal firing. It also inhibits the release of glutamate, an excitatory neurotransmitter, thereby reducing excessive neuronal activity. These combined effects make it effective as an anticonvulsant and mood stabilizer.","oneSentence":"Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:36.757Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy (partial seizures, generalized tonic-clonic seizures, Lennox-Gastaut syndrome)"},{"name":"Bipolar disorder maintenance treatment (bipolar depression)"}]},"trialDetails":[{"nctId":"NCT06184581","phase":"PHASE4","title":"Lithium Versus Lamotrigine in Bipolar Disorder, Type II","status":"RECRUITING","sponsor":"University Hospital Bispebjerg and Frederiksberg","startDate":"2024-05-08","conditions":"Bipolar II Disorder","enrollment":200},{"nctId":"NCT03689114","phase":"PHASE4","title":"Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-05-10","conditions":"Epilepsies, Partial","enrollment":58},{"nctId":"NCT00838279","phase":"PHASE1","title":"Lamotrigine 25 mg Chewable Tablets, Fasting","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-02","conditions":"Healthy","enrollment":32},{"nctId":"NCT00838136","phase":"PHASE1","title":"Lamotrigine 25 mg Chewable Tablets, Non-Fasting","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-02","conditions":"Healthy","enrollment":32},{"nctId":"NCT00835263","phase":"PHASE1","title":"Bioequivalence Study of 200 mg Lamotrigine Tablet Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-01","conditions":"Healthy","enrollment":32},{"nctId":"NCT00834561","phase":"PHASE1","title":"Bioequivalence Study of 200 mg Lamotrigine Tablet Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-01","conditions":"Healthy","enrollment":32},{"nctId":"NCT05881928","phase":"PHASE4","title":"Effect of Adding Lamotrigine to Sodium Valproate in Childhood Epilepsy: Clinicolabratory Study","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-07-29","conditions":"Epilepsy, Lamotrigine, Sodium Valproate Adverse Reaction","enrollment":50},{"nctId":"NCT00647751","phase":"PHASE1","title":"Food Study of Lamotrigine Tablets 25 mg to Lamictal® Tablets 25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2004-08","conditions":"Healthy","enrollment":28},{"nctId":"NCT00650208","phase":"PHASE1","title":"Fasting Study of Lamotrigine Tablets 25 mg to Lamictal® Tablets 25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2004-07","conditions":"Healthy","enrollment":27},{"nctId":"NCT05450822","phase":"","title":"Precision Medicine in the Treatment of Epilepsy","status":"RECRUITING","sponsor":"Gitte Moos Knudsen","startDate":"2022-02-18","conditions":"Epilepsy","enrollment":550},{"nctId":"NCT04602221","phase":"PHASE1","title":"A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-12-01","conditions":"Healthy","enrollment":40},{"nctId":"NCT06199791","phase":"PHASE1","title":"Single-dose, Two-way Crossover Bioequivalence of Lamotrigine in Healthy Male Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Desitin Arzneimittel GmbH","startDate":"2023-04-03","conditions":"Fasting","enrollment":24},{"nctId":"NCT05748236","phase":"PHASE4","title":"The Efficacy and Safety of Lamotrigine Versus Carbamazepine in Focal Epilepsy","status":"UNKNOWN","sponsor":"Dhaka Medical College","startDate":"2022-11-01","conditions":"Focal Epilepsy","enrollment":70},{"nctId":"NCT05639257","phase":"NA","title":"Treatment of Myotonia - Lamotrigine Versus Namuscla","status":"UNKNOWN","sponsor":"Grete Andersen, MD","startDate":"2022-12-05","conditions":"Non-Dystrophic Myotonia","enrollment":32},{"nctId":"NCT05017155","phase":"PHASE3","title":"MExiletine Versus Lamotrigine in Non-Dystrophic Myotonias","status":"UNKNOWN","sponsor":"University College, London","startDate":"2021-08-12","conditions":"Non-Dystrophic Myotonia","enrollment":60},{"nctId":"NCT04938856","phase":"PHASE1","title":"Bioequivalence of Lamnet (Lamotrigine)100mg Tablet With the Reference Product Lamictal 100mg (Lamotrigine) Tablet Under Fasting Conditions","status":"COMPLETED","sponsor":"University of Karachi","startDate":"2020-09-04","conditions":"Bioequivalence","enrollment":26},{"nctId":"NCT05145608","phase":"PHASE1","title":"Comparative Bioavailability Study of Lamotrigine ER Tablets USP 50 mg","status":"COMPLETED","sponsor":"Alembic Pharmaceuticals Ltd.","startDate":"2018-01-10","conditions":"Bioequivalence","enrollment":22},{"nctId":"NCT01995825","phase":"PHASE4","title":"Lamotrigine Bioequivalence","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2012-05","conditions":"Epilepsy","enrollment":35},{"nctId":"NCT00088452","phase":"PHASE3","title":"Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2004-07","conditions":"Childhood Absence Epilepsy, Petit Mal Epilepsy, Epilepsy","enrollment":453},{"nctId":"NCT03116828","phase":"PHASE4","title":"A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2017-07-07","conditions":"Epilepsy With Partial On-set Seizures","enrollment":102},{"nctId":"NCT02821338","phase":"PHASE1","title":"A Bioavailability Crossover Study of Two Formulations of Lamotrigine Extended Release Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2016-06","conditions":"Healthy","enrollment":30},{"nctId":"NCT02256124","phase":"PHASE2, PHASE3","title":"Effect of Lamotrigine on Cognition in NF1","status":"TERMINATED","sponsor":"Erasmus Medical Center","startDate":"2014-10","conditions":"Neurofibromatosis Type 1","enrollment":41},{"nctId":"NCT01674010","phase":"PHASE2","title":"Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder","status":"TERMINATED","sponsor":"OPKO Health, Inc.","startDate":"2012-08","conditions":"Bipolar 1 Disorder","enrollment":309},{"nctId":"NCT04015687","phase":"PHASE1","title":"A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults","status":"COMPLETED","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2019-07-15","conditions":"Healthy Participants","enrollment":22},{"nctId":"NCT02404168","phase":"PHASE4","title":"BEEP Follow Up: Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2015-07-07","conditions":"Epilepsy","enrollment":4},{"nctId":"NCT00419003","phase":"PHASE4","title":"Research Study for Major Depressive Disorder: Investigation of Glutamate Medications","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2006-12","conditions":"Major Depression","enrollment":26},{"nctId":"NCT03898011","phase":"PHASE1","title":"A Bioequivalence Study of Two Formulations Lamotrigine 100 mg Tablets and Lamictal 100 mg Tablets in Healthy Adult Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Pharmtechnology LLC","startDate":"2019-03-23","conditions":"Healthy Adults","enrollment":28},{"nctId":"NCT02989727","phase":"PHASE4","title":"Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2003-11","conditions":"Depression, Bipolar Disorder, Bipolar Depression","enrollment":150},{"nctId":"NCT00243152","phase":"NA","title":"Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI","status":"COMPLETED","sponsor":"Pain and Analgesia Imaging and Neuroscience Group","startDate":"2005-10","conditions":"Facial Neuropathy","enrollment":6},{"nctId":"NCT00916149","phase":"NA","title":"Cognitive Effects of Treatment of Interictal Discharges","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2007-01","conditions":"Epilepsy","enrollment":31},{"nctId":"NCT02413918","phase":"PHASE4","title":"Iloperidone in Mixed States of Bipolar Disorder","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2012-04","conditions":"Bipolar Disorder","enrollment":41},{"nctId":"NCT02100644","phase":"PHASE4","title":"Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-12","conditions":"Epilepsy","enrollment":33},{"nctId":"NCT00939614","phase":"PHASE1","title":"Study of Lamotrigine 2×25 mg IR Tablets of Torrent Pharmaceuticals Limited, India and Lamictal® (Lamotrigine) 2×25 mg Tablets of GlaxoSmithKline, USA, in Healthy Human Adult Subjects, Under Fasting Conditions.","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT00939458","phase":"PHASE1","title":"Study of Lamotrigine 2 x 25 mg IR Tablets of Torrent Pharmaceuticals Pvt., Ltd., India and Lamictal ® (Lamotrigine) 2 x 25 mg Tablets of Glaxo-SmithKline, USA, in Healthy Human Adult Subjects, Under Fed Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT00144872","phase":"PHASE1","title":"LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-11-01","conditions":"Seizure, Absence","enrollment":54},{"nctId":"NCT01357902","phase":"PHASE1","title":"Lamotrigine Bioequivalence Study to Compare Dispersible Tables With Compressed Tablets in China","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-18","conditions":"Epilepsy","enrollment":24},{"nctId":"NCT01891890","phase":"PHASE3","title":"Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)","status":"TERMINATED","sponsor":"Emory University","startDate":"2013-08","conditions":"Epilepsy, Partial, Epilepsy, Localization Related","enrollment":72},{"nctId":"NCT00410371","phase":"PHASE1","title":"Study to Compare Two Formulations of Lamotrigine in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-12-28","conditions":"Mental Disorders","enrollment":96},{"nctId":"NCT00605371","phase":"PHASE1","title":"Bioequivalence and Food Effect of 250mg of Lamotrigine XR","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-01-15","conditions":"Epilepsy","enrollment":209},{"nctId":"NCT00449774","phase":"PHASE1","title":"Bioequivalence And Effect Of Food And Water On Lamotrigine in Healthy Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05-07","conditions":"Mental Disorders","enrollment":220},{"nctId":"NCT00412191","phase":"PHASE1","title":"Bioequivalence And Lack Of Food Effects Of 300mg Lamotrigine XR","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-06","conditions":"Epilepsy","enrollment":180},{"nctId":"NCT00627575","phase":"PHASE1","title":"AED/Statin Interaction Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02-04","conditions":"Epilepsy","enrollment":119},{"nctId":"NCT00907985","phase":"PHASE1","title":"A Study to Evaluate the Effect of Single Doses of Drug A (Lamotrigine) and Drug B (Vofopitant) Alone and in Combination on Resting Motor Threshold in Healthy Subjects","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-05-15","conditions":"Bipolar Disorder","enrollment":12},{"nctId":"NCT01879423","phase":"PHASE1","title":"The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 5mg×5 Compared With Lamotrigine Compressed Tablet 25mg in Chinese Healthy Male Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-04-28","conditions":"Epilepsy","enrollment":24},{"nctId":"NCT02064465","phase":"PHASE1","title":"The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 100mg Compared With Compressed Tablet 100 mg","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-03-15","conditions":"Epilepsy","enrollment":138},{"nctId":"NCT02513654","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-09-06","conditions":"Bipolar Disorder","enrollment":16},{"nctId":"NCT01602510","phase":"PHASE3","title":"Lamotrigine Phase III Study in Bipolar I Disorder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-08","conditions":"Bipolar Disorder","enrollment":265},{"nctId":"NCT00355082","phase":"PHASE3","title":"Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05","conditions":"Epilepsy, Partial","enrollment":226},{"nctId":"NCT00579982","phase":"PHASE3","title":"An Open-Label Trial Measuring Satisfaction And Convenience Of Two Formulations Of Lamotrigine In Subjects With A Mood Disorder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-01","conditions":"Mood Disorders","enrollment":97},{"nctId":"NCT01376180","phase":"","title":"Drug Use Investigation for LAMICTAL","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12","conditions":"Epilepsy","enrollment":3000},{"nctId":"NCT01863602","phase":"","title":"Special Drug Use Investigation for LAMICTAL® (Long Term)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04","conditions":"Epilepsy","enrollment":850},{"nctId":"NCT01428518","phase":"","title":"Special Drug Use Investigation for LAMICTAL Bipolar","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11","conditions":"Bipolar Disorder","enrollment":1036},{"nctId":"NCT01939561","phase":"PHASE3","title":"Lamotrigine as Treatment of Myotonia","status":"COMPLETED","sponsor":"Grete Andersen, MD","startDate":"2013-11","conditions":"Dystrophia Myotonica Type 1, Myotonia Congenita, Paramyotonia Congenita","enrollment":27},{"nctId":"NCT00272025","phase":"PHASE1","title":"Treatment Resistant Bipolar Depression","status":"TERMINATED","sponsor":"Queen's University","startDate":"2006-10","conditions":"Bipolar Depression","enrollment":1},{"nctId":"NCT00621842","phase":"PHASE3","title":"Lamotrigine for Symptoms of Geriatric Bipolar Depression","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2008-01","conditions":"Bipolar Disorder, Depression, Bipolar","enrollment":57},{"nctId":"NCT00277212","phase":"PHASE4","title":"A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-12","conditions":"Bipolar Disorder","enrollment":1169},{"nctId":"NCT00321516","phase":"PHASE1","title":"Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-07","conditions":"Bipolar Disorder","enrollment":20},{"nctId":"NCT01888757","phase":"PHASE1","title":"Lamotrigine Extended-Release Tablets 50 mg Under Fed Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2010-09","conditions":"Healthy","enrollment":62},{"nctId":"NCT01888731","phase":"PHASE1","title":"Bioequivalence Study of Lamotrigine Extended-Release Tablets 50 mg Under Fasting Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2010-08","conditions":"Healthy","enrollment":62},{"nctId":"NCT01888263","phase":"PHASE1","title":"Bioequivalence Study of Lamotrigine Extended-Release Tablets 200mg Under Fed Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2010-08","conditions":"Healthy","enrollment":32},{"nctId":"NCT01888250","phase":"PHASE1","title":"Bioequivalence Study of Lamotrigine Extended-Release Tablets 200mg Under Fasting Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2010-08","conditions":"Healthy","enrollment":36},{"nctId":"NCT00292461","phase":"PHASE3","title":"A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2006-03","conditions":"Epilepsy","enrollment":64},{"nctId":"NCT01618825","phase":"PHASE1","title":"Bioequivalence Study of Lamotrigine Tablets 25 mg (2 x 25 mg Tablets) Under Fed Condition","status":"COMPLETED","sponsor":"IPCA Laboratories Ltd.","startDate":"2012-03","conditions":"Fed","enrollment":28},{"nctId":"NCT01618799","phase":"PHASE1","title":"Bioequivalence Study of Lamotrigine Tablets 25 mg (2 x 25 mg Tablets) Under Fasting Condition","status":"COMPLETED","sponsor":"IPCA Laboratories Ltd.","startDate":"2012-03","conditions":"Fasting State","enrollment":28},{"nctId":"NCT01513720","phase":"PHASE1","title":"Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fasting Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2002-12","conditions":"Healthy","enrollment":20},{"nctId":"NCT01513681","phase":"PHASE1","title":"Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fed Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2002-11","conditions":"Healthy","enrollment":20},{"nctId":"NCT00277641","phase":"PHASE3","title":"Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity","status":"COMPLETED","sponsor":"Lindner Center of HOPE","startDate":"2006-03","conditions":"Binge Eating Disorder, Obesity","enrollment":70},{"nctId":"NCT01131949","phase":"PHASE1","title":"Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets of Dr.Reddy's Under Fasting Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2003-01","conditions":"Healthy","enrollment":26},{"nctId":"NCT01131975","phase":"PHASE1","title":"Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets of Dr.Reddy's Under Fed Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2003-01","conditions":"Healthy","enrollment":26},{"nctId":"NCT00901407","phase":"NA","title":"Lamotrigine Augmentation in Resistant Depression","status":"COMPLETED","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2003-12","conditions":"Unipolar Depression","enrollment":138},{"nctId":"NCT00634062","phase":"PHASE4","title":"Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder","status":"COMPLETED","sponsor":"Mclean Hospital","startDate":"2004-12","conditions":"Borderline Personality Disorder","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lamitrin, Lamogin","Test Group (Lamnet 100 mg), Reference Group (Lamictal 100 mg)","Lamotrigine","Lamictal XR"],"phase":"marketed","status":"active","brandName":"Lamotrigine tablet","genericName":"Lamotrigine tablet","companyName":"Dhaka Medical College","companyId":"dhaka-medical-college","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability. Used for Epilepsy (partial seizures, generalized tonic-clonic seizures, Lennox-Gastaut syndrome), Bipolar disorder maintenance treatment (bipolar depression).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}